To include your compound in the COVID-19 Resource Center, submit it here.

Exelixis shares dip after 4Q earnings

Exelixis Inc. (NASDAQ:EXEL) fell $2.42 to $27.11 on Tuesday after reporting late Monday sales of Cabometyx cabozantinib

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE